Literature DB >> 22833238

Assessment of efficacy of pamidronate in undifferentiated spondyloarthropathy (uSpA): a molecular mechanism.

Hamid Namazi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22833238     DOI： 10.1007/s00296-012-2454-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  7 in total

1.  Assessment of efficacy of pamidronate in undifferentiated spondyloarthropathy (uSpA): a placebo control trial in a tertiary level center.

Authors:  Rathindra Nath Sarkar; Sibaji Phaujdar; Dibyendu De; Kuntal Bhattacharyya
Journal:  Rheumatol Int       Date:  2011-12-27       Impact factor: 2.631

2.  Chronic axial compression of the mouse tail segment induces MRI bone marrow edema changes that correlate with increased marrow vasculature and cellularity.

Authors:  M Owen Papuga; Steven T Proulx; Edmund Kwok; Zhigang You; Paul T Rubery; Paul E Dougherty; Matthew J Hilton; Hani A Awad; Edward M Schwarz
Journal:  J Orthop Res       Date:  2010-09       Impact factor: 3.494

3.  Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

Authors:  Volker Viereck; Günter Emons; Vanessa Lauck; Karl-Heinz Frosch; Sabine Blaschke; Carsten Gründker; Lorenz C Hofbauer
Journal:  Biochem Biophys Res Commun       Date:  2002-03-01       Impact factor: 3.575

Review 4.  Bisphosphonates: mode of action and pharmacology.

Authors:  R Graham G Russell
Journal:  Pediatrics       Date:  2007-03       Impact factor: 7.124

5.  Involvement of cholesterol in osteoclast-like cell formation via cellular fusion.

Authors:  T Sato; I Morita; S Murota
Journal:  Bone       Date:  1998-08       Impact factor: 4.398

Review 6.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

7.  Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients.

Authors:  Zhiming Lin; Jieruo Gu; Peigen He; Jiesheng Gao; Xiaoxia Zuo; Zhizhong Ye; Fengmin Shao; Feng Zhan; Jinying Lin; Li Li; Yanlin Wei; Manlong Xu; Zetao Liao; Qu Lin
Journal:  Rheumatol Int       Date:  2009-12-13       Impact factor: 2.631
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.